Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 12:07PM ET
0.6999
Dollar change
-0.0262
Percentage change
-3.61
%
Index- P/E- EPS (ttm)-8.17 Insider Own1.84% Shs Outstand2.44M Perf Week-16.68%
Market Cap1.71M Forward P/E- EPS next Y-3.56 Insider Trans5.90% Shs Float2.40M Perf Month-28.22%
Income-11.66M PEG- EPS next Q-1.30 Inst Own20.75% Short Float7.36% Perf Quarter-6.80%
Sales0.00M P/S- EPS this Y38.02% Inst Trans-28.65% Short Ratio0.53 Perf Half Y-51.40%
Book/sh3.13 P/B0.22 EPS next Y43.13% ROA-92.08% Short Interest0.18M Perf Year-88.29%
Cash/sh3.47 P/C0.20 EPS next 5Y- ROE-112.46% 52W Range0.50 - 12.27 Perf YTD-7.91%
Dividend Est.- P/FCF- EPS past 5Y69.19% ROI-161.68% 52W High-94.30% Beta1.45
Dividend TTM- Quick Ratio4.01 Sales past 5Y-46.20% Gross Margin- 52W Low39.98% ATR (14)0.11
Dividend Ex-Date- Current Ratio4.01 EPS Y/Y TTM24.13% Oper. Margin0.00% RSI (14)39.76 Volatility12.35% 13.87%
Employees9 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price4.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q63.73% Payout- Rel Volume0.64 Prev Close0.73
Sales Surprise- EPS Surprise20.28% Sales Q/Q- EarningsNov 09 AMC Avg Volume331.12K Price0.70
SMA20-23.26% SMA50-9.65% SMA200-54.12% Trades Volume92,056 Change-3.61%
Date Action Analyst Rating Change Price Target Change
Aug-05-20Initiated H.C. Wainwright Buy $4
Mar-21-24 07:30AM
Mar-13-24 02:00PM
Mar-06-24 10:30AM
Jan-31-24 08:00AM
Dec-07-23 08:00AM
04:30PM Loading…
Nov-09-23 04:30PM
07:30AM
Nov-03-23 12:00PM
Oct-12-23 11:00AM
Oct-11-23 07:30AM
Sep-06-23 07:30AM
Aug-21-23 07:30AM
Aug-10-23 04:30PM
Jun-02-23 01:30PM
May-31-23 08:00AM
07:30AM Loading…
May-24-23 07:30AM
May-18-23 12:00PM
May-16-23 07:30AM
May-11-23 05:00PM
Apr-20-23 02:20PM
Apr-18-23 12:10PM
07:30AM
Apr-17-23 07:30AM
Mar-22-23 05:05PM
Feb-22-23 07:30AM
Feb-13-23 07:30AM
Feb-10-23 07:30AM
Jan-25-23 08:30AM
Jan-06-23 04:30PM
01:30PM
04:15PM Loading…
Dec-21-22 04:15PM
Nov-10-22 06:25PM
05:05PM
09:00AM
Oct-25-22 12:00PM
Oct-12-22 09:38AM
Oct-07-22 05:42PM
Oct-06-22 07:30AM
Sep-29-22 08:30AM
Sep-27-22 03:51PM
Sep-26-22 12:09PM
Sep-22-22 07:30AM
Sep-12-22 07:30AM
Aug-11-22 05:00PM
Jul-11-22 06:53AM
Jun-06-22 02:15PM
May-16-22 12:22PM
08:00AM
May-12-22 04:50PM
May-05-22 08:33AM
May-03-22 07:30AM
May-02-22 04:30PM
07:30AM
Apr-26-22 10:15AM
Apr-18-22 09:30AM
Apr-11-22 03:39PM
10:41AM
Apr-08-22 01:00PM
Mar-22-22 05:00PM
Mar-08-22 04:30PM
Feb-22-22 09:30AM
Jan-11-22 12:30PM
07:30AM
Jan-03-22 07:30AM
Dec-06-21 09:28AM
Nov-12-21 07:00AM
Nov-10-21 04:40PM
Oct-18-21 07:05AM
Oct-07-21 09:00AM
Sep-30-21 08:05AM
Sep-16-21 12:12PM
08:08AM
07:40AM
07:05AM
Sep-03-21 07:05AM
Aug-31-21 08:05AM
Aug-12-21 05:00PM
Jul-07-21 04:30PM
Jun-22-21 11:04AM
Jun-14-21 04:09PM
08:00AM
Jun-04-21 08:00AM
May-13-21 05:00PM
May-11-21 01:10PM
08:00AM
Apr-29-21 07:30AM
Apr-12-21 07:33AM
Apr-10-21 08:30AM
Mar-25-21 05:15PM
Mar-11-21 07:30AM
Mar-01-21 08:00AM
Feb-17-21 04:15PM
Feb-12-21 07:00AM
Jan-25-21 05:14PM
Jan-21-21 03:33PM
Jan-04-21 04:15PM
Nov-19-20 07:30AM
Nov-10-20 05:00PM
Nov-09-20 08:00AM
Oct-26-20 07:30AM
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bitterman Robert JPresident & CEOFeb 26 '24Buy0.912,5002,27518,990Feb 27 04:42 PM
Bitterman Robert JPresident & CEOJul 01 '23Buy2.841,0002,84019,211Jul 05 06:00 PM
Bitterman Robert JPresident & CEOJun 30 '23Buy2.881,0002,88018,211Jul 05 06:00 PM
Ferrara Robert LDirectorJun 14 '23Buy3.102,0006,2006,000Jun 15 05:00 PM